Metvix

Methyl aminolevulinate, the active ingredient in Metvix, is a photosensitizer presented as a cream for topical use. It is employed in the management of actinic keratosis and superficial basal cell carcinoma in adult patients with appropriate skin lesions.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards, manufactures under EU GMP guidelines, and provides regulatory‑approved batches through a secure logistics network.

Metvix is used in photodynamic therapy for precancerous and early skin cancers.

- Actinic keratosis: clears precancerous lesions and reduces risk of progression. - Superficial basal cell carcinoma: achieves tumor eradication with minimal scarring.

Topical application of Metvix may be associated with local and systemic adverse reactions.

Common Side Effects: - Erythema: redness at the application site. - Edema: swelling of the treated area. - Pain or burning sensation during illumination. - Crusting or scaling of the skin. - Itching or mild irritation. - Hyperpigmentation: temporary darkening of the skin.

Serious or Rare Side Effects: - Severe photosensitivity reactions extending beyond the treated field. - Allergic dermatitis: widespread rash or hives. - Secondary infection of the treated lesion. - Persistent ulceration or scarring. - Systemic phototoxicity in rare cases.

Metvix should be used with careful consideration of patient and lesion characteristics.

- Confirm diagnosis: ensure lesion is appropriate for photodynamic therapy. - Sun avoidance: advise patients to avoid direct sunlight for at least 48 hours after treatment. - Protective clothing: recommend covering treated area with dressings or clothing during illumination. - Monitor for allergic reactions: discontinue if severe dermatitis develops. - Use caution in immunocompromised patients: assess risk of infection. - Store at room temperature: keep in original container, protect from light and moisture.

Metvix may interact with other agents that affect photosensitivity or wound healing.

Major Interactions (Avoid): - Systemic photosensitizing drugs (e.g., tetracyclines, sulfonamides). - Porphyrinogenic agents (e.g., phenobarbital, phenytoin). - Topical agents that cause severe irritation or ulceration.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may alter healing response. - Immunosuppressants: could increase infection risk. - Retinoids: may enhance skin irritation. - Anticoagulants: monitor for bleeding if extensive crusting occurs.